Metrion Biosciences awarded £637k funding under Innovate UK Biomedical Catalyst Primer Award for ion channel drug discovery

Notes to editors

Please download the full Press release to see editorial notes and Media contact information

Press Release

Metrion Biosciences awarded £637k funding under Innovate UK Biomedical Catalyst Primer Award for ion channel drug discovery

Cambridge, UK, 28th August 2018

• Funding will support project aiming to identify novel oral therapeutics for the auto-immune disease psoriasis
• Adds to Innovate UK funding awarded in February 2018 for research on potassium channel inhibitors

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has been awarded £637k funding under the Innovate UK Biomedical Catalyst Primer Award scheme. The funding will be used to support further research on orally available potassium channel inhibitors for treatment of psoriasis, a common auto-immune disease for which improved treatments are much needed.

The project will commence in September 2018, and will focus on the further optimisation of a set of key compounds, and their characterisation in disease relevant models. The compounds are taken from the portfolio acquired by Metrion in January this year of more than 2,000 small molecule inhibitors of a voltage-gated potassium channel known to be involved in the development of auto-immune disease. Metrion has already confirmed the potent in vitro activity of the selected key compounds, and has filed a new patent application covering a series of these active drug leads.

If successful, the project may lead to the selection of one or more novel oral drug candidates suitable for development as potential new therapeutics for the treatment of psoriasis and other auto-immune disorders. The cost of biologics for treatment of a patient with moderate-severe psoriasis is approximately $70K per year, and the global psoriasis drugs market is expected to be valued at $13 billion by 2024 with a CAGR of 7.26% (GlobalData, 2016). A novel efficacious oral drug at a cost effective price-point has the potential to profoundly reduce healthcare costs.

Dr Keith McCullagh, Chairman, Metrion Biosciences, said: “As well as being a specialist ion channel contract research organisation, Metrion also has valuable intellectual property in the potassium channel field which we are keen to see commercialised. The funding received from Innovate UK will enable us to determine the potential value of this novel therapeutic approach to auto-immune conditions. If successful, we will seek appropriate industry partners to fund further development and commercialisation.”

Alongside this project, Metrion is also conducting research with its compounds in other auto-immune conditions, partially funded by an Innovate UK Biomedical Catalyst Feasibility Award, announced in February.